Roya Khosravi-Far, Ph.D., PLD. President and CTO, is an established scientist with over 30 years of expertise advancing early discovery and translational research in cancer biology, cancer therapy and biomarker discovery. She was the driving force behind the core academic research while an Associate Professor of Pathology at Harvard Medical School and Beth Israel Deaconess Medical School, and now leads the PDAC science team at BiomaRx. She received her PhD at University of North Carolina at Chapel Hill, carried out a postdoctoral fellowship and Massachusetts Institute of Technology and obtained the certificate for Program in Leadership Development at Harvard Business School.
Benjamin Damien, Ph.D., MBA, CBO. Experienced in developing Biotech Spinoffs from R&D to market, including regulatory and clinical aspects. Director of BD at Univercells. CEO of Targetome, Nemesis Consulting, and BioXpr. PhD in Molecular Biology at university of Tuebingen and University of Liege. MS in Management at University of Namur and MBA at Solvay Business School.
Towia Libermann, Ph.D. Co-founder and chair of scientific advisory board. Precision Medicine thought leader. He is an Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Institute. He is director of the Genomics, Proteomics, Bioinformatics and Systems Biology Center at the Beth Israel Deaconess Medical Center as well as Director of the Dana Farber/Harvard Cancer Center Cancer Proteomics Core. Precision Medicine thought leader. He was co-founder of Tolerance Pharmaceuticals that merged with Cardion. Towia received his PhD at the Weizmann Institute of Science and carried out a postdoctoral fellowship at the Whitehead Institute.